David is a sought-after expert for accelerating marketing authorization, time to launch, early patient and market access in the European environment of orphan and advanced therapy medicinal products.
David’s experience includes rare oncology and haematology (ALL, AML, MM, CD30+ HL/NHL, CTCL, ALK+/EGFR+ NSCLC, breast cancer), metabolic and endocrine diseases (MPS, Graves’, acromegaly), neurology (CIDP, RTT, MG, narcolepsy, Friedrich’s ataxia), ophthalmic disorders (LCA), hepatic conditions (PSC), and rare immunological diseases (AMR, GvHD).
He is the author and co-author of numerous peer-reviewed publications, a rare disease, orphan drugs and gene therapies trainer, and speaker at international meetings (ISPOR, RAPS EU Congress, Orphan Drugs Development and Commercialization).
